PROMOTE: Promotion of the Mind Through Exercise

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by University of British Columbia
Sponsor:
Collaborators:
Canadian Stroke Network
Heart and Stroke Foundation of Canada
Information provided by (Responsible Party):
University of British Columbia
ClinicalTrials.gov Identifier:
NCT01027858
First received: December 7, 2009
Last updated: February 20, 2014
Last verified: February 2014
  Purpose

The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of aerobic-based exercise training for maintaining cognitive function, executive function, and everyday function in adults with mild vascular cognitive impairment.


Condition Intervention
Vascular Cognitive Impairment
Behavioral: Aerobic-based exercise training
Behavioral: CON (control; usual care)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Role of Exercise on Cognition and Function in Seniors With Vascular Cognitive Impairment: A Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • This is a proof-of-concept study. The primary endpoints are: ADAS-Cog [ Time Frame: baseline, 6 months, and 12 months ] [ Designated as safety issue: No ]
  • EXIT-25 [ Time Frame: baseline, 6 months, and 12 months ] [ Designated as safety issue: No ]
  • ADCS-ADL [ Time Frame: baseline, 6 months, and 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary outcomes of interest include: performance of specific executive processes [ Time Frame: baseline, 6 months, and 12 months ] [ Designated as safety issue: No ]
  • Physical function [ Time Frame: baseline, 6 months, and 12 months ] [ Designated as safety issue: No ]
  • Inflammatory biomarkers [ Time Frame: baseline, 6 months, and 12 months ] [ Designated as safety issue: No ]
  • Serum glucose and lipids. These will be assessed at 6 and 12 months. [ Time Frame: baseline, 6 months, and 12 months ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Brain Structure [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    Volume and white matter lesions.

  • Brain Function [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: Yes ]
    fMRI and resting state


Estimated Enrollment: 70
Study Start Date: December 2009
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
AT (aerobic-based exercise training)
Behavioral: Aerobic-based exercise training
Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
Active Comparator: 2
CON (control; usual care)
Behavioral: CON (control; usual care)
Nutrition education and usual care as prescribed by neurologist

Detailed Description:

A total of 70 adults diagnosed with Ischaemic Vascular Cognitive Impairment (SIVCI) will be randomized to either a 6 month thrice weekly walking program or usual care. After 6 months of intervention, they will be followed for an additional 6 months. There will be three measurement sessions: baseline, 6 months (end of intervention period); and 12 months.

  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The study will specifically recruit individuals who fulfill the diagnostic criteria for SIVCI as outlined by Erkinjuntti and colleagues (1), which requires the presence of both cognitive syndrome (as defined in Section A below) and small vessel ischaemic disease (as defined in Section B below).

A. Cognitive Syndrome defined as:

  1. Dysexecutive Syndrome: Some impairment in goal formulation, initiation, planning, organizing, sequencing, executing, set-shifting and maintenance, or abstracting.
  2. Memory Deficit: Some impairment in recall, relative intact recognition, less severe forgetting, benefit from cues.
  3. Progression: Deterioration of A1 and A2 from a previous higher level of functioning that are not per se interfering with complex occupational and social activities.

B. Small Vessel Ischaemic Disease defined as:

  1. Evidence of relevant cerebrovascular disease by brain imaging (in the last 12 months) defined as the presence of both:

    i. Periventricular and deep white matter lesions: Patchy areas of low attenuation (intermediate density between that of normal white matter and that of intraventricular cerebro-spinal fluid) or diffuse symmetrical areas of low attenuation with ill defined margins extending to the centrum semiovale plus at least one lacunar infarct (correlating to the white matter grading scale greater than 3 from the Cardiovascular Health Study) (2,3); and ii. Absence of cortical and/or cortico-sub-cortical non-lacunar territorial infarcts and watershed infarcts, haemorrhages indicating large vessel disease, signs of normal pressure hydrocephalus, or other specific causes of white matter lesions (e.g., multiple sclerosis, leukodystrophies, sarcoidosis, brain irradiation, etc).

  2. Presence or a history of neurological signs as evidence for cerebrovascular disease such as hemiparesis, lower facial weakness, Babinski sign, sensory deficit, dysarthria, gait disorder, extrapyramidal signs consistent with sub-cortical brain lesion(s).

In addition, individuals must meet the following inclusion criteria:

  1. Montreal Cognitive Assessment (MoCA) (4) score less than 26 at screening;
  2. MMSE (5) score of > 20 at screening;
  3. Community-dwelling;
  4. Lives in Metro Vancouver;
  5. Have a caregiver, family member, or friend who interacts with him/her on a weekly basis;
  6. Able to comply with scheduled visits, treatment plan, and other trial procedures;
  7. Must be able to read, write, and speak English in which psychometric tests are provided with acceptable visual and auditory acuity;
  8. Stable on a fixed dose of cognitive medications (e.g., donepezil, galantamine, rivastigmine, memantine, etc.) that is not expected to change during the 12-month study period, or, if they are not on any of these medications, they are not expected to start them during the 12-month study period;
  9. Provide a personally signed and dated informed consent document indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. In addition, an assent form will be provided at baseline and again at regular intervals;
  10. Able to walk independently; and
  11. Must be in sufficient health to participate in study`s aerobic-based exercise training program. This will be based on medical history, vital signs, physical examination by study physicians, and written recommendation by family physician indicating individual`s appropriateness to participate in an aerobic-based exercise training program.

Exclusion Criteria:

  1. Absence of relevant small vessel ischaemic lesions on an existing brain computed tomography (CT) or MRI;
  2. Diagnosed with another type of dementia (e.g., AD) or other neurological conditions (e.g., multiple sclerosis, Parkinson's disease, etc.) that affects cognition and mobility;
  3. At high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level (i.e., Class C of the American Heart Risk Stratification Criteria);
  4. Have clinically significant peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility;
  5. Taking medications that may negatively affect cognitive function, such as anticholinergics, including agents with pronounced anticholinergic properties (e.g., amitriptyline), major tranquilizers (typical and atypical antipsychotics), and anticonvulsants (e.g., gabapentin, valproic acid, etc.); or
  6. Individual who plans to participate or is enrolled in a clinical drug trial concurrent to this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01027858

Contacts
Contact: Michelle Munkacsy, MHK 604 875 4111 ext 69056

Locations
Canada, British Columbia
University of British Columbia Recruiting
Vancouver, British Columbia, Canada
Contact: Michelle Munkacsy, MHK    604 875 4111 ext 69056    michelle.munkacsy@hiphealth.ca   
Sponsors and Collaborators
University of British Columbia
Canadian Stroke Network
Heart and Stroke Foundation of Canada
Investigators
Principal Investigator: Teresa Liu-Ambrose, Ph.D, PT University of British Columbia
Study Director: Janice Eng, Ph.D University of British Columbia
Study Director: Lara Boyd, Ph.D University of British Columbia
Study Director: Robin Hsiung, Ph.D University of British Columbia
Study Director: Claudia Jacova, Ph.D University of British Columbia
Study Director: Howard Feldman, MD University of British Columbia
Study Director: Penny Brasher, Ph.D University of British Columbia
Study Director: Philip Lee, Ph.D University of British Columbia
  More Information

No publications provided by University of British Columbia

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of British Columbia
ClinicalTrials.gov Identifier: NCT01027858     History of Changes
Other Study ID Numbers: H09-00529
Study First Received: December 7, 2009
Last Updated: February 20, 2014
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
exercise
aerobic exercise training
vascular cognitive impairment
Mild Sub-cortical Ischaemic Vascular Cognitive Impairment (SIVCI)

Additional relevant MeSH terms:
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on July 26, 2014